9. Tranexamic Acid in Trauma — The Therapeutic Time Window (PATCH-Trauma Update)

Quick Recap

Cross-cutting protocol — companion to Massive Transfusion Protocol (Hematology System), which references CRASH-2/CRASH-3 briefly; this protocol provides a fuller treatment of tranexamic acid in trauma specifically, including prehospital administration evidence and a genuinely important, very recent (2025) refinement of the drug's therapeutic time window that meaningfully narrows the traditionally taught "3-hour window."

1. Definition

Tranexamic acid (TXA): an antifibrinolytic agent that acts as a competitive inhibitor of plasminogen, blocking plasmin-mediated fibrin breakdown and thereby stabilizing clot formation — used in trauma to counteract the hyperfibrinolytic component of trauma-induced coagulopathy, a distinct but overlapping problem from the dilutional/consumptive coagulopathy addressed by the ratio-based resuscitation strategies in the Massive Transfusion Protocol.

Trauma-induced coagulopathy: an early, endogenous coagulopathy that can develop following major trauma, driven by tissue injury, shock, and hyperfibrinolysis — distinct from, though it can compound, the dilutional coagulopathy that develops from large-volume resuscitation; TXA specifically targets the hyperfibrinolytic component of this process.

The therapeutic time window: the central organizing concept of this entire evidence base — TXA's benefit is strongly, consistently time-dependent, with efficacy diminishing as time from injury to administration increases, and (per CRASH-2's own analysis) potentially reversing to harm beyond a certain delay. The precise duration of this window has itself been a genuinely evolving, recently revised question (Section 11), making this less a settled pharmacological fact and more an actively refined estimate.

2. Pathophysiology

Major trauma with significant hemorrhage triggers a systemic hyperfibrinolytic state as part of trauma-induced coagulopathy, in which excessive plasmin activity degrades forming clots before they can achieve adequate hemostasis — TXA's plasminogen-inhibiting mechanism directly counters this specific process. This mechanism explains the drug's pronounced time-dependency: hyperfibrinolysis is most active and most clinically consequential in the earliest period after major trauma, and the biological window during which inhibiting this process meaningfully alters the trajectory toward hemorrhagic death is inherently limited — once a patient has survived long enough for this acute hyperfibrinolytic phase to resolve or for irreversible hemorrhagic shock to have occurred, TXA's specific mechanism has correspondingly less to offer, and (per the harm signal discussed in Section 11) may even theoretically tip the balance toward pathological, unopposed clot stabilization in a physiological context that has already moved past the phase where this was beneficial.

3. Immediate Stabilization (ABCDE) — TXA as a Time-Critical Circulation Intervention

Not a standalone stabilization scenario; TXA administration sits within the Circulation component of trauma resuscitation (cross-reference Massive Transfusion Protocol and relevant Trauma System protocols):

Checklist:

4. Focused History

• Precise time of injury — the single most clinically important historical data point for this specific intervention, given the evidence's pronounced time-dependency
• Mechanism and suspected severity of hemorrhage/shock
• Suspected traumatic brain injury specifically (relevant to the separate, TBI-specific CRASH-3 evidence base, Section 11)
• Contraindications: known hypersensitivity, active/recent thromboembolic event history (relevant given the theoretical, though not strongly trial-confirmed, thrombotic risk concern)

5. Comprehensive System-wise Examination

• Cardiovascular: hemodynamic status, degree of shock (relevant to STAAMP's specific severe-shock subgroup finding, Section 11)
• Neurological: GCS and signs of traumatic brain injury (relevant to CRASH-3's TBI-specific population and finding)
• General: overall hemorrhage severity assessment informing the risk-benefit calculus, alongside the time-since-injury variable

POCUS integration: not a primary component of the TXA-specific decision, though relevant to the broader trauma hemorrhage assessment TXA administration sits within.

6. Syndrome Identification — Reframed as Time-Window Classification

• Administered within ~1 hour of injury: the population with the clearest, most consistently demonstrated mortality benefit across CRASH-2, STAAMP, and PATCH-Trauma (Section 11)
• Administered within the traditionally-taught 3-hour window (CRASH-2-derived): benefit demonstrated in CRASH-2's own analysis, though the more recent, more precisely-measured PATCH-Trauma exploratory analysis suggests the true effective window may be substantially shorter (Section 11) — a genuinely important, evolving refinement
• Administered beyond 3 hours: CRASH-2's own exploratory analysis found TXA unexpectedly associated with increased mortality in this later-administration population — a real, if imprecisely-measured, harm signal that should discourage routine late administration
• Significant traumatic brain injury, mild-to-moderate severity: the specific population where CRASH-3 demonstrated a mortality benefit (Section 11) — a population-specific finding distinct from the general hemorrhagic-trauma evidence base

7. Differential Diagnosis — Not a Traditional Differential

Cross-reference relevant Trauma System protocols for the underlying diagnostic and severity assessment of the traumatic injury itself; this protocol addresses the TXA administration decision specifically.

8. Severity/Risk Assessment

Time since injury: the dominant, most consistently identified determinant of TXA's risk-benefit balance across this entire evidence base — more influential than most other individual patient factors in determining expected benefit.

Degree of shock: STAAMP's subgroup analysis specifically found improved survival concentrated in patients with severe shock (systolic blood pressure <70 mmHg) who received TXA within 1 hour, suggesting shock severity may specifically modify the degree of benefit within the time-sensitive window, though this remains a subgroup (not primary, pre-specified) finding.

TBI severity: CRASH-3 demonstrated benefit specifically in mild-to-moderate TBI — a population-specific stratification distinct from the general hemorrhagic-trauma time-window framework.

9. Investigations — Not a Primary Diagnostic Workup

Relevant "investigation" is accurate, precise documentation of time since injury — the single most consequential data point for this protocol's decision-making, more so than most laboratory or imaging findings.

10. Point-of-Care Ultrasound — Not a Primary Component

Relevant only insofar as it contributes to the broader trauma hemorrhage assessment (cross-reference relevant Trauma System protocols), not specifically to the TXA administration decision.

11. Evidence-Based Management — The Full Evidence Arc, Including a Genuinely Recent Refinement

CRASH-2 (2010) — The Foundational Trial

• CRASH-2 trial: a large, international RCT (predominantly conducted in low- and middle-income countries) demonstrating that TXA reduces mortality among trauma patients with suspected significant bleeding when administered within 3 hours of injury
• Exploratory time-to-treatment analysis: found the mortality benefit was specifically associated with time between injury and first TXA dose — benefit evident up to 3 hours, with the greatest benefit when administered within 1 hour (mortality 5.3% vs. 7.7%) — and, notably, TXA appeared unexpectedly associated with increased mortality when given later than 3 hours, a genuine, if less statistically robust, harm signal at the tail end of the delay spectrum
• A specific, important methodological limitation of CRASH-2's own time-window data: the trial's data-collection form required personnel to record an "estimated number of hours since injury" rather than an exact, precisely-measured time — meaning the granularity and precision underlying the celebrated "3-hour window" figure was itself somewhat imprecise, a limitation that becomes directly relevant to interpreting the more recent, more precisely-measured PATCH-Trauma findings below
• Individual patient-level data meta-analysis of TXA trials in acute severe bleeding (2017): found that while immediate treatment substantially improves survival, the survival benefit decreases by approximately 10% for every 15 minutes of treatment delay, up to 3 hours, after which no benefit was demonstrated — a striking, clinically vivid quantification of the time-dependency principle, directly informing subsequent guideline emphasis on minimizing any delay to administration

CRASH-3 (2019) — The Traumatic Brain Injury-Specific Evidence Base

• CRASH-3 trial: a separate, dedicated international RCT specifically examining TXA in traumatic brain injury — found reduced mortality specifically among patients with mild-to-moderate TBI, a population-specific finding distinct from the general hemorrhagic-trauma evidence above
• This represents a separate, distinct evidence base from CRASH-2/PATCH-Trauma, addressing a different population and injury mechanism (TBI-specific head injury death, rather than general hemorrhagic mortality) — clinicians should recognize these as complementary but non-interchangeable indications

STAAMP (2020) — Prehospital Evidence, Genuinely Mixed Overall Result with an Important Subgroup Signal

• STAAMP trial (Guyette et al., 2020): a US-based RCT specifically evaluating prehospital TXA administration, enrolling 927 trauma patients at risk for hemorrhage — did not demonstrate a statistically significant reduction in 30-day mortality across all participants, the overall, primary trial result
• However, subgroup analyses showed improved survival specifically among patients who received TXA within 1 hour of injury and those with severe shock (systolic BP <70 mmHg) — a post hoc finding of mortality 4.6% vs. 7.6% in the within-1-hour subgroup, directionally consistent with, and reinforcing, CRASH-2's own within-1-hour finding, even though STAAMP's overall trial result was null
• Practical significance: this is a genuinely important pattern worth recognizing — an overall null trial result can still contain a clinically meaningful, directionally consistent subgroup signal, particularly when that subgroup finding aligns with a separately, independently derived finding from a different trial (CRASH-2) testing the same underlying time-dependency hypothesis; this should be weighed as more informative than either finding considered entirely in isolation, while still retaining appropriate caution given both are subgroup/exploratory analyses

⚠️ PATCH-Trauma (2023–2025) — The Most Recent, Most Precisely-Measured Refinement of the Time Window

• PATCH-Trauma trial (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage): a prehospital RCT specifically testing whether prehospital TXA administration increases survival with favorable functional outcome at 6 months — a more patient-centered, longer-horizon outcome than the 28-day, survival-only endpoints used in CRASH-2/CRASH-3
• Primary finding: a bolus of 1g TXA plus 1g infused over 8 hours significantly reduced 28-day mortality, consistent with CRASH-2's mortality finding — but found no association between TXA and favorable functional outcomes at 6 months, a genuinely important, sobering distinction between short-term survival benefit and longer-term, patient-centered functional recovery that CRASH-2/CRASH-3 (which did not follow patients beyond 28 days or report functional outcomes) could not address
• No increased incidence of vascular occlusive events was observed in the TXA group compared to placebo, providing some reassurance on the theoretical thrombotic risk concern, at least within this trial's specific population and follow-up period
• ⚠️ A genuinely recent (2025), exploratory time-window analysis of PATCH-Trauma data — this represents new evidence refining a long-taught clinical principle: using exact, field-recorded time measurements (rather than CRASH-2's estimated-hours methodology), this analysis found the therapeutic window during which TXA administration was associated with reduced 28-day mortality appeared to be approximately half as long as the traditionally-cited 3-hour CRASH-2-derived window — closer to 90 minutes than 3 hours
• Proposed explanation for this discrepancy: the PATCH-Trauma analysis used precise, field-measured administration times, whereas CRASH-2 relied on estimated hours since injury — the greater measurement precision in PATCH-Trauma may have revealed a narrower true therapeutic window that CRASH-2's coarser measurement methodology could not resolve; additionally, CRASH-2 enrolled patients receiving TXA up to 8 hours from injury, and the patient population receiving TXA at the later end of that range may have diluted or obscured a narrower true window in the original analysis
• This is consistent with, and reinforces, STAAMP's post hoc within-1-hour finding — three independent analyses (CRASH-2's own within-1-hour subgroup, STAAMP's post hoc within-1-hour subgroup, and PATCH-Trauma's more precisely-measured exploratory window analysis) now converge on the theme that the earliest possible administration, likely within roughly 60–90 minutes, captures the great majority of TXA's mortality benefit, with the traditionally-taught "3-hour window" potentially representing an overestimate of the true, precisely-measured effective duration

Practical Synthesis

TXA should be administered as early as possible after major traumatic hemorrhage is recognized, ideally in the prehospital setting where systems allow, with the clearest, most consistent benefit concentrated in the first 60–90 minutes after injury — clinicians should not treat "within 3 hours" as a comfortable, leisurely target given this more recent, more precisely-measured evidence suggesting the true effective window may be substantially narrower than traditionally taught. Late administration (beyond 3 hours) should generally be avoided, given CRASH-2's own signal of potential harm at this end of the spectrum. For traumatic brain injury specifically, the separate CRASH-3 evidence base applies, supporting benefit in mild-to-moderate TBI. PATCH-Trauma's finding of a 28-day mortality benefit without a corresponding 6-month functional outcome benefit is a genuinely important, underappreciated nuance — TXA appears to help more patients survive the acute event without necessarily translating into a demonstrated improvement in longer-term, patient-centered functional recovery among survivors, a distinction worth explicitly acknowledging rather than assuming survival benefit automatically implies proportionate long-term functional benefit.

12. Organ Support

Interacts directly with Massive Transfusion Protocol (Hematology System) for the broader hemorrhage resuscitation framework TXA administration sits within, and with relevant Trauma System protocols for the overall trauma management context.

13. Disease-Specific Therapy

• Standard TXA regimen (per CRASH-2 and PATCH-Trauma protocols): 1g IV bolus, followed by 1g infused over 8 hours
• Timing is the dominant, most clinically actionable variable: administer as early as possible, ideally within 60–90 minutes of injury per the most recent, most precisely-measured evidence, and avoid administration beyond 3 hours given the signal of potential harm at this later point
• CRASH-3 TBI-specific indication: applies to mild-to-moderate TBI as a separate, population-specific consideration from the general hemorrhagic-trauma indication above

14. Consultation Matrix

15. Monitoring Framework

• Clinical: hemodynamic response, ongoing hemorrhage trajectory
• Time tracking: precise time from injury to TXA administration documented as a specific, prognostically relevant data point, given the evidence's pronounced time-dependency
• Escalation triggers: not directly applicable to the TXA decision itself; ongoing hemorrhage management follows the relevant Massive Transfusion and Trauma System protocols

16. ICU Bundle Checklist

17. Complications

Early:

• Theoretical vascular occlusive/thrombotic events — not confirmed as an increased risk in PATCH-Trauma's specific population and follow-up period, though this remains a longstanding, biologically plausible theoretical concern given the drug's antifibrinolytic mechanism

Late:

• Potential mortality harm signal specifically with administration beyond 3 hours post-injury, per CRASH-2's exploratory analysis
• Absence of demonstrated 6-month functional outcome benefit despite 28-day mortality benefit, per PATCH-Trauma — not a "complication" per se, but an important limitation on the drug's demonstrated benefit profile worth explicit acknowledgment

Prevention: early, prompt administration within the narrowest reliably-beneficial window; avoidance of late administration beyond 3 hours

Rescue: not directly applicable; standard trauma resuscitation principles apply regardless of TXA administration status

18. Escalation & De-escalation — Not Directly Applicable

Cross-reference Massive Transfusion Protocol and relevant Trauma System protocols for the broader escalation framework TXA administration sits within.

19. ICU Discharge Criteria — Not Directly Applicable

20. Documentation & Medicolegal Checklist

• Precise time of injury and time of TXA administration documented, given the evidence's pronounced time-dependency
• TXA administration decision and rationale documented, including if administration was deferred or declined due to being beyond the effective time window
• TBI-specific indication (if applicable) documented separately from the general hemorrhagic-trauma indication

21. Key Guidelines

• Trauma resuscitation guidelines internationally have incorporated TXA administration within 3 hours of injury, based on the original CRASH-2-derived window — clinicians should be aware that this traditionally-cited window has not been independently replicated with the same precision, and the most recent (2025), more precisely-measured evidence suggests the true effective window may be substantially narrower, an update not yet fully reflected in existing guideline documents at the time of this protocol's writing

22. Landmark Trials

23. Controversies

• The genuinely recent narrowing of the therapeutic window is the central, most clinically actionable controversy this protocol addresses: for over a decade, "within 3 hours" has been the standard, guideline-endorsed teaching point for TXA administration in trauma — the 2025 PATCH-Trauma exploratory analysis, using more precise measurement methodology than CRASH-2's original estimated-time data, suggests this window may be closer to 90 minutes. This protocol presents this as a genuine, evidence-driven refinement rather than either dismissing it as merely an exploratory/post hoc finding not yet warranting practice change, or treating it as a fully settled replacement for the traditional teaching — clinicians should be aware that this specific parameter is under active revision and should prioritize the earliest possible administration regardless of exactly where the outer boundary of benefit ultimately settles.
• Reconciling short-term survival benefit with the absence of demonstrated long-term functional benefit (PATCH-Trauma): this is a genuinely important, underappreciated tension — CRASH-2 and CRASH-3 did not measure long-term functional outcomes, meaning the field's enthusiasm for TXA has been substantially built on short-term mortality data alone; PATCH-Trauma's more complete outcome assessment reveals that surviving the acute event does not automatically translate into demonstrated improved 6-month functional status, a nuance that should inform, without necessarily reversing, the strong practice consensus favoring early TXA administration.
• The theoretical thrombotic risk concern remains incompletely resolved despite reassuring trial-level data: PATCH-Trauma's specific population and follow-up period did not show excess vascular occlusive events, and this reassurance is broadly consistent with the accumulated trial evidence across this drug's use in trauma, but the theoretical, mechanism-based concern (an antifibrinolytic agent promoting pathological clot stabilization) has not been definitively, mechanistically excluded across all populations and use contexts.
• Generalizability of CRASH-2's predominantly low- and middle-income-country trial population to high-income trauma systems with different baseline trauma care, transport times, and resource availability remains a longstanding, only partially addressed generalizability question — STAAMP and PATCH-Trauma's more recent, high-income-country-based data help address this gap, but the foundational CRASH-2 evidence base itself originated in a meaningfully different care context.

24. References

1. CRASH-2 collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32.
2. CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101.
3. Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40,138 bleeding patients. Lancet. 2018;391(10116):125-132.
4. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713-1723.
5. Guyette FX, Brown JB, Zenati MS, et al. Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury: a double-blind, placebo-controlled, randomized clinical trial (STAAMP). JAMA Surg. 2020;156(1):11-20.
6. Mitra B, Mazur S, Cameron PA, et al. Tranexamic acid for trauma: filling the 'GAP' in evidence with the PATCH-Trauma trial. Emerg Med Australas. 2014.
7. PATCH-Trauma Investigators. Prehospital tranexamic acid for severe trauma. N Engl J Med. 2023.
8. Tranexamic acid timing and mortality impact after trauma: exploratory analysis of the PATCH-Trauma trial. Ann Emerg Med. 2025.
9. Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015;5:CD004896.
10. Effectiveness and safety of tranexamic acid use in acute traumatic injury in the prehospital and in-hospital settings: a systematic review and meta-analysis of randomized controlled trials. 2021.
11. The Washington Manual of Critical Care, 4th ed. 2025 — trauma resuscitation chapter.
12. ICU Protocols: A Step-wise Approach, 2nd ed. — relevant trauma content; ATLS 11th Edition (2023) — hemorrhage control content.